Zalicus, Inc. (extinct)

Zalicus, Inc. (extinct)

Zalicus, Inc. (extinct)

Overview
Date Founded

2000

Headquarters

245 1st Street,3rd floor,Cambridge, MA 02142

Type of Company

Private

Employees (Worldwide)

11 - 50

Industries

Pharmaceuticals
Medical Support Services
Hospitals & Patient Services
Biotechnology

Company Description

Zalicus is a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain. Zalicus has a portfolio of proprietary clinical-stage product candidates targeting pain, including Z160, an N-type calcium channel blocker for chronic neuropathic pain and Z944, a T-type calcium channel blocker for acute and inflammatory pain. We have entered into multiple revenue-generating collaborations with large pharmaceutical companies relating to other products, product candidates and drug discovery technologies. Zalicus applies its expertise in the discovery and development of selective ion channel modulators and its combination high throughput screening capabilities to discover innovative therapeutics for itself and its collaborators in the areas of pain, inflammation, oncology and infectious disease.

Executives & Employees

Executive Vice President, Product Development

Paths to Zalicus, Inc.
Potential Connections via
Relationship Science
You
Zalicus, Inc.
Recent Transactions
Details Hidden

Zalicus, Inc. purchases EPIRUS Biopharmaceuticals, Inc. (Inactive) resulting in a new company EPIRUS Biopharmaceuticals, Inc.

Details Hidden

Horizon Discovery Group PLC purchases Zalicus, Inc. /Combinatorx Service Business from Zalicus, Inc. resulting in a new company Horizon CombinatoRx, Inc.

Details Hidden

Zalicus, Inc. raised money in a private placement transaction

Transaction Advisors
Legal Advisor

Advised onZalicus, Inc. purchases EPIRUS Biopharmaceuticals, Inc. (Inactive) resulting in a new company EPIRUS Biopharmaceuticals, Inc.

Investment Advisor

Advised onZalicus, Inc. purchases EPIRUS Biopharmaceuticals, Inc. (Inactive) resulting in a new company EPIRUS Biopharmaceuticals, Inc.

Investment Advisor

Advised onZalicus, Inc. purchases EPIRUS Biopharmaceuticals, Inc. (Inactive) resulting in a new company EPIRUS Biopharmaceuticals, Inc.

Legal Advisor

Advised onZalicus, Inc. purchases EPIRUS Biopharmaceuticals, Inc. (Inactive) resulting in a new company EPIRUS Biopharmaceuticals, Inc.

Legal Advisor

Advised onZalicus, Inc. purchases EPIRUS Biopharmaceuticals, Inc. (Inactive) resulting in a new company EPIRUS Biopharmaceuticals, Inc.

Associate

Advised onZalicus, Inc. purchases EPIRUS Biopharmaceuticals, Inc. (Inactive) resulting in a new company EPIRUS Biopharmaceuticals, Inc.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Zalicus, Inc.. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Zalicus, Inc.'s profile does not indicate a business or promotional relationship of any kind between RelSci and Zalicus, Inc..